Source: Healio News
In this video, Saad Usmani, MD, division chief of plasma cell disorders and director of clinical research in hematologic malignancies at Levine Cancer Institute/Atrium Health, offers insights regarding abstracts on developments in chimeric antigen receptor T-cell therapy at ASH Annual Meeting and Expo. Topics included a CAR-T 21 data update, exploratory studies looking at combining the fully human BCMA-directed CAR-T with a gamma secretase inhibitor, a larger study on allogeneic CAR T-cell therapy for multiple myeloma, and a first of its kind study on MCARH 109 in patients with relapse